Expression of Steroid Receptors in Endometrium

This study has been completed.
Sponsor:
Information provided by:
Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:
NCT00436462
First received: February 16, 2007
Last updated: November 6, 2009
Last verified: November 2009
  Purpose

Expression of steroid receptors in endometrium during ovarian stimulation.


Condition
Endometrium

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Expression of Steroid Receptors in Endometrium During the Early Follicular Phase in Stimulated Cycles

Further study details as provided by Aristotle University Of Thessaloniki:

Primary Outcome Measures:
  • Steroid receptors expression in endometrium during early follicular phase [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • In which day:day o+2, day 0+4 or day HCG [ Time Frame: 1 month ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples Without DNA

endometrial tissue


Estimated Enrollment: 30
Study Start Date: December 2005
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this study is to examine in stimulated cycles a) whether there is a difference in expression of steroid receptors in stroma and glands of endometrium between different days during the follicular phase b)whether there are secretory changes detected by endometrium histology before ovulation c)whether there is an association between expression of steroid receptors in endometrium and exposure to oestradiol and progesterone during the follicular phase.

  Eligibility

Ages Eligible for Study:   20 Years to 39 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

infertile women

Criteria

Inclusion Criteria:

  • Treatment by IUI,
  • BMI:18-29KGR/M2,
  • No previous ovarian surgery,
  • Normal hysterosalpingography,
  • Estradiol < 80pg/ml and progesterone < 1.6ng/ml on day 2 of the cycle

Exclusion Criteria:

  • Endometriosis,
  • Severe male factor
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00436462

Locations
Greece
Unit of Human Reproduction, 1st Department of Obstetrics & Gynecology, AUTH, Papageorgiou Hospital
Thessaloniki, Greece, 56429
Sponsors and Collaborators
Aristotle University Of Thessaloniki
Investigators
Study Director: Basil C Tarlatzis, MD,PhD Unit of Human Reproduction, 1st Department of Obst & Gyn, Aristotle University of Thessaloniki, Papageorgiou Hospital, Greece
  More Information

Publications:
Responsible Party: Unit for Human Reproduction, Aristotle University of Thessaloniki
ClinicalTrials.gov Identifier: NCT00436462     History of Changes
Other Study ID Numbers: UHR-4
Study First Received: February 16, 2007
Last Updated: November 6, 2009
Health Authority: Greece: Ministry of Health and Welfare

Keywords provided by Aristotle University Of Thessaloniki:
Steroid receptors
Endometrium
IVF
Follicular phase

ClinicalTrials.gov processed this record on July 20, 2014